{"id":"W4367296836","doi":"10.1212/wnl.0000000000202287","title":"Safety and Clinical Efficacy Outcomes From the Long-term Extension Study of Tolebrutinib in Participants With Relapsing Multiple Sclerosis: 2.5-Year Results (S16.010)","year":2023,"lang":"en","type":"article","venue":"Neurology","topic":"Acute Lymphoblastic Leukemia research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Toronto; St. Michael's Hospital","funders":"","keywords":"Medicine; Discontinuation; Adverse effect; Expanded Disability Status Scale; Multiple sclerosis; Internal medicine; Upper respiratory tract infection; Physical therapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":{"n_in":0,"stratum":"aff_core","weight":5595.2375,"opus":{"tier":"OUT","genre":"empirical","about_ca":false,"confidence":"high","reason":"Long-term extension results on safety and efficacy of tolebrutinib in relapsing multiple sclerosis; a clinical trial report."},"gpt":{"tier":"OUT","genre":"empirical","about_ca":false,"confidence":"high","reason":"This reports long-term clinical trial safety and efficacy outcomes, not research itself."},"grok":{"tier":"OUT","genre":"empirical","about_ca":false,"confidence":"high","reason":"Clinical long-term safety/efficacy results for tolebrutinib in multiple sclerosis."}},"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.007457724,0.001074545,0.001699148,0.0003997482,0.0006819912,0.001238524,0.00089442,0.001580171,0.007922846],"category_scores_gemma":[0.004302336,0.0003937304,0.003331193,0.0006027202,0.0004047445,0.001128483,0.0006617943,0.003562627,0.002018165],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007307181,"about_ca_system_score_gemma":0.001604713,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001299253,"about_ca_topic_score_gemma":0.003805154,"domain_scores_codex":[0.9984633,0.0007410341,0.0001280649,0.0001812129,0.000265327,0.0002211339],"domain_scores_gemma":[0.9961298,0.0006308739,0.001239476,0.0003467664,0.0006094421,0.001043714],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.7718586,0.009555518,0.04684989,0.002509783,0.01188517,0.0003807694,0.0003368245,0.001245703,0.01042942,0.0004736967,0.03236256,0.1121121],"study_design_scores_gemma":[0.500991,0.1597079,0.3023751,0.0005894048,0.009914784,0.0006331911,0.0001878841,0.001141135,0.003751219,0.001220379,0.01932062,0.0001673496],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9159281,0.01259566,0.001453198,0.003063143,0.0005400819,0.004178573,0.05007391,0.0002701444,0.01189719],"genre_scores_gemma":[0.9333243,0.003215169,0.002895061,0.003646222,0.0005700247,0.004765567,0.04284111,0.00007337436,0.00866921],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.007922846,"threshold_uncertainty_score":0,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1191918278459601,"score_gpt":0.3665534081011015,"score_spread":0.2473615802551414,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}